116 related articles for article (PubMed ID: 12699060)
1. Negative CEA values in metastatic colorectal carcinoma and the likelihood of complete chemotherapy response.
Tomasevic Z; Jelic S; Nikolic L; Filipovic I; Stamatovic L; Radosavljevic D
Int J Biol Markers; 2003; 18(1):28-32. PubMed ID: 12699060
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Oh ST; Kim JG; Choi MH; Lee MA
Cancer Res Treat; 2018 Jan; 50(1):283-292. PubMed ID: 28494536
[TBL] [Abstract][Full Text] [Related]
3. Threshold Change in CEA as a Predictor of Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA.
Gulhati P; Yin J; Pederson L; Schmoll HJ; Hoff P; Douillard JY; Hecht JR; Tournigand C; Tebbut N; Chibaudel B; Gramont A; Shi Q; Overman MJ
J Natl Cancer Inst; 2020 Nov; 112(11):1127-1136. PubMed ID: 32191317
[TBL] [Abstract][Full Text] [Related]
4. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
5. Biliary carcinoembryonic antigen levels in diagnosis of occult hepatic metastases from colorectal carcinoma.
Waisberg J; Palma RT; Neto LC; Martins LC; Oliveira MS; Nagashima CA; Godoy AC; Goffi FS
World J Gastroenterol; 2003 Jul; 9(7):1589-93. PubMed ID: 12854170
[TBL] [Abstract][Full Text] [Related]
6. Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer?
Selcukbiricik F; Bilici A; Tural D; Erdamar S; Soyluk O; Buyukunal E; Demirelli F; Serdengecti S
Tumour Biol; 2013 Aug; 34(4):2233-9. PubMed ID: 23625655
[TBL] [Abstract][Full Text] [Related]
7. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
Moretto R; Rossini D; Conca V; Lonardi S; Rasola C; Antoniotti C; Santini D; Marmorino F; Tomasello G; Borelli B; Caponnetto S; Zucchelli G; Zaniboni A; Ambrosini M; Buonadonna A; Fanchini L; Cupini S; Masi G; Falcone A; Cremolini C
Br J Cancer; 2021 Sep; 125(6):839-845. PubMed ID: 34253871
[TBL] [Abstract][Full Text] [Related]
8. Baseline and On-Treatment Markers Determining Prognosis of First-Line Chemotherapy in Combination with Bevacizumab in Patients with Metastatic Colorectal Cancer.
Quidde J; Denne L; Kutscheidt A; Kindler M; Kirsch A; Kripp M; Petersen V; Schulze M; Seraphin J; Tummes D; Arnold D; Stein A
Oncol Res Treat; 2017; 40(1-2):21-26. PubMed ID: 28192780
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response.
Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Lee MA
Asia Pac J Clin Oncol; 2018 Jun; 14(3):239-246. PubMed ID: 29044941
[TBL] [Abstract][Full Text] [Related]
10. Serum carcinoembryonic antigen levels in patients operated for colorectal carcinoma.
Veingerl B
Wien Klin Wochenschr; 2001; 113 Suppl 3():32-8. PubMed ID: 15503618
[TBL] [Abstract][Full Text] [Related]
11. Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer.
Wang WS; Lin JK; Lin TC; Chiou TJ; Liu JH; Fan FS; Yen CC; Chen WS; Jiang JK; Yang SH; Wang HS; Chen PM
Int J Colorectal Dis; 2001 Apr; 16(2):96-101. PubMed ID: 11355325
[TBL] [Abstract][Full Text] [Related]
12. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer.
Kim G; Jung EJ; Ryu CG; Hwang DY
Yonsei Med J; 2013 Jan; 54(1):116-22. PubMed ID: 23225807
[TBL] [Abstract][Full Text] [Related]
14. Serum carcinoembryonic antigen levels and proliferating cell nuclear antigen labeling index for patients with colorectal carcinoma. Correlation with tumor progression and survival.
Nakamura T; Tabuchi Y; Nakae S; Ohno M; Saitoh Y
Cancer; 1996 Apr; 77(8 Suppl):1741-6. PubMed ID: 8608572
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
Aldrighetti L; Castoldi R; Di Palo S; Arru M; Stella M; Orsenigo E; Gavazzi F; Ferla G; Di Carlo V; Staudacher C
Chir Ital; 2005; 57(5):555-70. PubMed ID: 16241086
[TBL] [Abstract][Full Text] [Related]
16. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G;
Cancer Invest; 2012 Jan; 30(1):65-71. PubMed ID: 22236191
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for the early detection of relapses in metastatic colorectal cancers.
Chereches G; Barbos O; Buiga R; Balacescu O; Iancu D; Todor N; Balacescu L; Miron N; Bejinariu N; Ciuleanu TE
J BUON; 2017; 22(3):658-666. PubMed ID: 28730771
[TBL] [Abstract][Full Text] [Related]
18. Circulating carcinoembryonic antigen in pancreatic carcinoma.
Kalser MH; Barkin JS; Redlhammer D; Heal A
Cancer; 1978 Sep; 42(3 Suppl):1468-71. PubMed ID: 709516
[TBL] [Abstract][Full Text] [Related]
19. Serum carcinoembryonic antigen pre-operative level in colorectal cancer: revisiting risk stratification.
Iacuzzo C; Germani P; Troian M; Cipolat Mis T; Giudici F; Osenda E; Bortul M; de Manzini N
ANZ J Surg; 2021 Jun; 91(6):E367-E374. PubMed ID: 33870621
[TBL] [Abstract][Full Text] [Related]
20. Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases?
Bakalakos EA; Burak WE; Young DC; Martin EW
Am J Surg; 1999 Jan; 177(1):2-6. PubMed ID: 10037299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
